Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00024
|
|||||
Drug Name |
L-glutamine
|
|||||
Synonyms |
AES-14; Aesgen-14; E-6014; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; NutreStore; Saforis
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Short bowel syndrome [ICD11:KB89.1] | Approved | [1] | |||
Structure |
|
![]() |
||||
3D MOL | 2D MOL | |||||
Formula |
C5H10N2O3
|
|||||
Canonical SMILES |
C(CC(=O)N)C(C(=O)O)N
|
|||||
InChI |
InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1
|
|||||
InChIKey |
ZDXPYRJPNDTMRX-VKHMYHEASA-N
|
|||||
CAS Number |
CAS 56-85-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 146.14 | Topological Polar Surface Area | 106 | ||
Heavy Atom Count | 10 | Rotatable Bond Count | 4 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 4 | |||
XLogP |
-3.1
|
|||||
PubChem CID | ||||||
PubChem SID |
10527678
,11341651
,11361834
,11363005
,11365567
,11368129
,11372411
,11375176
,11376291
,11485070
,11487236
,11489193
,11491231
,11493523
,11493945
,11537712
,14710661
,14719601
,15297396
,17405112
,24277983
,24872884
,24895088
,24895232
,24895254
,24895310
,24895342
,26612133
,26679268
,26747519
,29224984
,3133338
,3364
,46393493
,46505866
,46508385
,47291275
,47365367
,47810918
,48416059
,49737762
,584498
,6436322
,7847083
,7887912
,8143908
,8153704
,828106
,836113
,841114
|
|||||
ChEBI ID |
ChEBI:18050
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | ASCT2 | Transporter Info | Alanine/serine/cysteine/threonine transporter 2 | Substrate | [2] | |
LAT1 | Transporter Info | L-type amino acid transporter 1 | Substrate | [3] | ||
SNAT1 | Transporter Info | Sodium-coupled neutral amino acid transporter 1 | Substrate | [4] | ||
SNAT2 | Transporter Info | Sodium-coupled neutral amino acid transporter 2 | Substrate | [4] | ||
SNAT3 | Transporter Info | Sodium-coupled neutral amino acid transporter 3 | Substrate | [4] | ||
SNAT4 | Transporter Info | Sodium-coupled neutral amino acid transporter 4 | Substrate | [4] | ||
SNAT5 | Transporter Info | Sodium-coupled neutral amino acid transporter 5 | Substrate | [4] | ||
SNAT7 | Transporter Info | Putative sodium-coupled neutral amino acid transporter 7 | Substrate | [4] | ||
References | ||||||
1 | L-glutamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5. | |||||
3 | Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009 Feb 6;136(3):521-34. | |||||
4 | Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11. |
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.